S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Odonate Therapeutics Stock Forecast, Price & News

+0.04 (+3.81%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
104,048 shs
Average Volume
1.22 million shs
Market Capitalization
$41.95 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for Odonate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Odonate Therapeutics logo

About Odonate Therapeutics

Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.


Odonate Therapeutics, Inc. (ODT)
October 27, 2021 |  uk.finance.yahoo.com
Odonate Therapeutics Inc.
August 26, 2021 |  barrons.com
August 21, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$3.53 per share


Net Income
$-126.35 million
Pretax Margin




Free Float
Market Cap
$41.95 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.17 out of 5 stars

Medical Sector

434th out of 1,418 stocks

Pharmaceutical Preparations Industry

198th out of 684 stocks

Analyst Opinion: 2.9Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

Is Odonate Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Odonate Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ODT, but not buy additional shares or sell existing shares.
View analyst ratings for Odonate Therapeutics
or view top-rated stocks.

How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ODT stock has decreased by 95.8% and is now trading at $1.09.
View which stocks have been most impacted by COVID-19

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a decrease in short interest in December. As of December 31st, there was short interest totaling 379,600 shares, a decrease of 35.8% from the December 15th total of 591,500 shares. Based on an average daily volume of 841,500 shares, the short-interest ratio is currently 0.5 days. Currently, 1.2% of the shares of the company are short sold.
View Odonate Therapeutics' Short Interest

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Odonate Therapeutics

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics, Inc. (NASDAQ:ODT) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.33.
View Odonate Therapeutics' earnings history

What price target have analysts set for ODT?

4 Wall Street analysts have issued 12-month price objectives for Odonate Therapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Odonate Therapeutics' stock price to reach $4.00 in the next year. This suggests a possible upside of 267.0% from the stock's current price.
View analysts' price targets for Odonate Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Kevin C. Tang, Chairman & Chief Executive Officer
  • Ryan Cole, Senior Vice President-Operations
  • Michael S. Hearne, Chief Financial Officer
  • Thomas Wei, Chief Scientific Officer
  • Steven Pfeiffer, Senior Vice President-Technical Operations

What other stocks do shareholders of Odonate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Boeing (BA), Bausch Health Companies (BHC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), AbbVie (ABBV), Apellis Pharmaceuticals (APLS), Athenex (ATNX), BioCryst Pharmaceuticals (BCRX) and CRISPR Therapeutics (CRSP).

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $1.09.

How much money does Odonate Therapeutics make?

Odonate Therapeutics has a market capitalization of $41.95 million. The company earns $-126.35 million in net income (profit) each year or ($2.72) on an earnings per share basis.

How many employees does Odonate Therapeutics have?

Odonate Therapeutics employs 145 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

Where are Odonate Therapeutics' headquarters?

Odonate Therapeutics is headquartered at 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 731-8180 or via email at [email protected].

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.